Regulus Therapeutics (NASDAQ:RGLS) Given New $10.00 Price Target at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS) had its target price increased by HC Wainwright from $9.00 to $10.00 in a research note released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Regulus Therapeutics’ Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.20) EPS.

A number of other brokerages have also commented on RGLS. SVB Leerink initiated coverage on shares of Regulus Therapeutics in a research report on Monday, March 18th. They issued an outperform rating and a $6.00 price objective on the stock. StockNews.com initiated coverage on shares of Regulus Therapeutics in a research report on Tuesday, April 16th. They issued a sell rating on the stock. Leerink Partnrs reissued an outperform rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. Wells Fargo & Company boosted their target price on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the stock an equal weight rating in a report on Wednesday, March 13th. Finally, Canaccord Genuity Group lowered their target price on shares of Regulus Therapeutics from $12.00 to $11.00 and set a buy rating on the stock in a report on Tuesday, March 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $11.75.

Regulus Therapeutics Stock Performance

Shares of RGLS opened at $2.03 on Tuesday. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79. The firm’s 50 day moving average price is $2.24 and its two-hundred day moving average price is $1.91. The firm has a market cap of $132.58 million, a P/E ratio of -1.39 and a beta of 1.64.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.14). On average, sell-side analysts anticipate that Regulus Therapeutics will post -0.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RGLS. Victory Capital Management Inc. increased its holdings in shares of Regulus Therapeutics by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 38,529 shares during the last quarter. Opaleye Management Inc. acquired a new position in shares of Regulus Therapeutics in the first quarter valued at $490,000. Vanguard Group Inc. increased its holdings in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares during the last quarter. FMR LLC increased its holdings in shares of Regulus Therapeutics by 32.4% in the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 716,000 shares during the last quarter. Finally, CVI Holdings LLC acquired a new position in shares of Regulus Therapeutics in the first quarter valued at $4,050,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.